MA35056B1 - Stratification à base de bcma et traitement pour patients atteints de myélome multiple - Google Patents

Stratification à base de bcma et traitement pour patients atteints de myélome multiple

Info

Publication number
MA35056B1
MA35056B1 MA36351A MA36351A MA35056B1 MA 35056 B1 MA35056 B1 MA 35056B1 MA 36351 A MA36351 A MA 36351A MA 36351 A MA36351 A MA 36351A MA 35056 B1 MA35056 B1 MA 35056B1
Authority
MA
Morocco
Prior art keywords
bcma
multiple myeloma
patients
treatment
cells
Prior art date
Application number
MA36351A
Other languages
English (en)
Inventor
Eric Borges
Jasmin Barbara Hebeis
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44343806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35056(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA35056B1 publication Critical patent/MA35056B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des procédés pour la stratification d'un patient atteint de myélome multiple (MM) comprenant l'étape consistant à déterminer si des lymphocytes B, de préférence des lymphocytes B malins dudit patient expriment ou non la protéine BCMA sur leur surface. De plus, des procédés pour sélectionner une thérapie du myélome multiple (MM) à base d'anticorps sont basés sur le fait que BCMA est exprimé ou non sur la surface cellulaire de lymphocytes B, de préférence des lymphocytes B malins d'un patient. La présente invention concerne en outre des thérapies à base d'anticorps pour des patients qui ont des lymphocytes B malins positifs pour BCMA.
MA36351A 2011-04-21 2012-04-20 Stratification à base de bcma et traitement pour patients atteints de myélome multiple MA35056B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163558 2011-04-21
PCT/EP2012/057248 WO2012143498A1 (fr) 2011-04-21 2012-04-20 Stratification basée sur bcma et thérapie pour les patients atteints de myélome multiple

Publications (1)

Publication Number Publication Date
MA35056B1 true MA35056B1 (fr) 2014-04-03

Family

ID=44343806

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36351A MA35056B1 (fr) 2011-04-21 2012-04-20 Stratification à base de bcma et traitement pour patients atteints de myélome multiple

Country Status (18)

Country Link
US (3) US20130101599A1 (fr)
EP (1) EP2699259B1 (fr)
JP (1) JP2014520248A (fr)
KR (1) KR20140031905A (fr)
CN (1) CN103608039A (fr)
AP (1) AP2013007178A0 (fr)
AU (1) AU2012244676A1 (fr)
CA (1) CA2832510A1 (fr)
CL (1) CL2013003031A1 (fr)
CO (1) CO6801644A2 (fr)
EA (1) EA201301180A1 (fr)
IL (1) IL228701A0 (fr)
MA (1) MA35056B1 (fr)
MX (1) MX2013012167A (fr)
PE (1) PE20140612A1 (fr)
SG (1) SG194500A1 (fr)
TN (1) TN2013000412A1 (fr)
WO (1) WO2012143498A1 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013340799B2 (en) 2012-11-01 2018-08-09 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2762497A1 (fr) 2013-02-05 2014-08-06 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP2762496A1 (fr) 2013-02-05 2014-08-06 EngMab AG Procédé pour la sélection d'anticorps contre BCMA
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
CA2900529A1 (fr) * 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Methodes de diagnostic, de pronostic et de surveillance ameliorees pour un myelome multiple, une leucemie lymphoide chronique et un lymphome non hodgkinien a lymphocytes b
BR112016018100A2 (pt) 2014-02-07 2018-02-20 Univ Mcmaster acoplador antigênico de células t trifuncional, métodos e usos do mesmo
RU2749041C2 (ru) * 2014-04-30 2021-06-03 Макс-Дельбрюк-Центрум Фюр Молекуляре Медицин Ин Дер Хельмхольтц - Гемайншафт Гуманизированные антитела против cd269 (bcma)
EP2982692A1 (fr) 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP3023437A1 (fr) 2014-11-20 2016-05-25 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP3029068A1 (fr) 2014-12-03 2016-06-08 EngMab AG Anticorps bispécifiques contre du CD3epsilon et BCMA pour utilisation dans le traitement de maladies
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
JP6892822B2 (ja) 2014-12-05 2021-06-23 メモリアル スローン ケタリング キャンサー センター Ｂ細胞成熟化抗原を標的化する抗体および使用の方法
SG10201912823PA (en) * 2015-04-13 2020-02-27 Pfizer Therapeutic antibodies and their uses
MX2018001398A (es) 2015-08-03 2018-05-28 Engmab Sarl Anticuerpos monoclonales contra bcma.
CN108350076B (zh) 2015-08-17 2022-06-07 詹森药业有限公司 抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
AU2016347516A1 (en) * 2015-10-30 2018-05-10 Glaxosmithkline Intellectual Property Development Limited Prognostic method
US11698369B2 (en) 2016-01-12 2023-07-11 Oncotracker, Inc. Methods for monitoring immune status of a subject
IL311107A (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
EP3471773A4 (fr) 2016-06-21 2020-07-08 Teneobio, Inc. Anticorps se liant à cd3
PT4050034T (pt) 2016-09-14 2024-05-27 Teneoone Inc Anticorpos de ligação a cd3
EP4295918A3 (fr) * 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Anticorps bispécifiques contre bcma et cd3 et médicament dans le traitement du myélome multiple
IL300729A (en) * 2016-12-21 2023-04-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2018144535A1 (fr) 2017-01-31 2018-08-09 Novartis Ag Traitement du cancer à l'aide de protéines chimères du récepteur de lymphocytes t ayant de multiples spécificités
WO2018151836A1 (fr) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Traitements d'association pour le traitement de cancers associés à bcma et de troubles auto-immuns
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
WO2018231949A1 (fr) 2017-06-14 2018-12-20 Dana-Farber Cancer Institute, Inc. Nanoparticules dirigées contre un antigène de maturation des lymphocytes b (bcma)
IL271194B2 (en) * 2017-06-20 2024-10-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2018237006A1 (fr) 2017-06-20 2018-12-27 Teneoone, Inc. Anticorps uniquement à chaînes lourdes anti-bcma
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
CN111094353A (zh) * 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
JP7137619B2 (ja) * 2017-09-29 2022-09-14 モガム・インスティテュート・フォー・バイオメディカル・リサーチ Ｂｃｍａに対して高い親和性を有する抗ｂｃｍａ抗体およびそれを含むがんの処置のための医薬組成物
JP7227630B2 (ja) 2017-10-12 2023-02-22 マックマスター ユニバーシティー Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
EP3697436A1 (fr) 2017-10-18 2020-08-26 Novartis AG Compositions et méthodes pour la dégradation sélective d'une protéine
WO2019089969A2 (fr) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
CN111902159A (zh) 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
WO2019152660A1 (fr) 2018-01-31 2019-08-08 Novartis Ag Polythérapie utilisant un récepteur antigénique chimérique
EP3752203A1 (fr) 2018-02-13 2020-12-23 Novartis AG Thérapie par récepteur antigénique chimérique en combinaison avec il-15 r et il15
KR20210011002A (ko) 2018-05-16 2021-01-29 얀센 바이오테크 인코포레이티드 암을 치료하는 방법 및 t-세포 재유도 치료제의 효능을 향상시키는 방법
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
EP3844265A2 (fr) 2018-08-31 2021-07-07 Novartis AG Procédés de fabrication de cellules exprimant un récepteur d'antigène chimère
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CA3118191A1 (fr) * 2018-10-31 2020-05-07 Glaxosmithkline Intellectual Property Development Limited Procedes de traitement du cancer
CN113412127A (zh) 2019-02-25 2021-09-17 诺华股份有限公司 用于病毒递送的介孔二氧化硅颗粒组合物
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
WO2020210678A1 (fr) 2019-04-12 2020-10-15 Novartis Ag Procédés de fabrication de cellules exprimant un récepteur antigénique chimérique
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
MX2021015337A (es) 2019-06-14 2022-01-18 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
BR112022010206A2 (pt) 2019-11-26 2022-11-29 Novartis Ag Receptores de antígeno quiméricos e usos dos mesmos
JP2023515211A (ja) 2020-02-27 2023-04-12 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
BR112022017148A2 (pt) 2020-02-27 2022-11-08 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
BR112022022800A2 (pt) 2020-05-11 2022-12-13 Janssen Biotech Inc Métodos para tratamento de mieloma múltiplo
WO2021234560A1 (fr) 2020-05-19 2021-11-25 Janssen Biotech, Inc. Compositions comprenant un agent thérapeutique de redirection des lymphocytes t et un inhibiteur de la voie d'adhésion vla 4
EP4165169A1 (fr) 2020-06-11 2023-04-19 Novartis AG Inhibiteurs de zbtb32 et leurs utilisations
MX2022016342A (es) 2020-06-30 2023-01-24 Teneobio Inc Union de anticuerpos multiespecificos a bcma.
EP4199960A2 (fr) 2020-08-21 2023-06-28 Novartis AG Compositions et méthodes pour la génération in vivo de cellules exprimant car
CN112698037B (zh) * 2021-03-25 2021-06-25 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
EP4330381A1 (fr) 2021-04-27 2024-03-06 Novartis AG Système de production de vecteurs viraux
CA3173810A1 (fr) 2021-06-01 2022-12-01 Andreas Bader Coupleurs d'antigene de lymphocytes t de claudine 18.2 et leurs utilisations
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
CN117858901A (zh) 2021-08-20 2024-04-09 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2024025967A1 (fr) * 2022-07-28 2024-02-01 Springworks Therapeutics, Inc. Détermination du taux de bcma sur des cellules plasmatiques par cytométrie de flux
WO2024089639A1 (fr) 2022-10-26 2024-05-02 Novartis Ag Formulations lentivirales
WO2024102954A1 (fr) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Système d'écrêtage induit par activation (aics)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
US8604172B2 (en) 2009-04-17 2013-12-10 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
JP5739326B2 (ja) 2008-04-25 2015-06-24 ザイモジェネティクス， インコーポレイテッド Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
PL2406284T3 (pl) * 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma

Also Published As

Publication number Publication date
US20160131655A1 (en) 2016-05-12
PE20140612A1 (es) 2014-06-07
CL2013003031A1 (es) 2014-08-18
AP2013007178A0 (en) 2013-10-31
EP2699259B1 (fr) 2016-07-27
AU2012244676A1 (en) 2013-10-24
CA2832510A1 (fr) 2012-10-26
MX2013012167A (es) 2013-12-10
EP2699259A1 (fr) 2014-02-26
IL228701A0 (en) 2013-12-31
TN2013000412A1 (en) 2015-03-30
JP2014520248A (ja) 2014-08-21
CN103608039A (zh) 2014-02-26
EA201301180A1 (ru) 2014-03-31
KR20140031905A (ko) 2014-03-13
US20140193433A1 (en) 2014-07-10
US20130101599A1 (en) 2013-04-25
CO6801644A2 (es) 2013-11-29
WO2012143498A1 (fr) 2012-10-26
SG194500A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
MA35056B1 (fr) Stratification à base de bcma et traitement pour patients atteints de myélome multiple
Gupta et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research
Wei et al. Differential phenotypes of tissue-infiltrating T cells during angiotensin II-induced hypertension in mice
MA41654B2 (fr) Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
MA35180B1 (fr) Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b
MA37619A1 (fr) Anticorps anti-fcrn
MA45504B1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
Benguigui et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response
WO2012118750A3 (fr) Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
MA34956B1 (fr) Therapeutique a base de levure pour infection chronique par l'hepatite b
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
Ponnuswamy et al. Angiotensin II synergizes with BAFF to promote atheroprotective regulatory B cells
MA38930A1 (fr) Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)
MA35165B1 (fr) Induction de tolérance immune par utilisation de méthotrexate
MX342907B (es) El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
NZ701652A (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
WO2007124309A3 (fr) Procédés de détection de mutations de l'acide nucléique de jak2
MA20150436A1 (fr) Préparation pharmaceutique
Li et al. Mercury impact on hematopoietic stem cells is regulated by IFNγ-dependent bone marrow-resident macrophages in mice
MA45124A (fr) Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
Pokrovskiy HIV epidemic in Russia and neighbouring countries
Hegazy et al. Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs